{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:09Z","timestamp":1791644769128,"version":"4.3.4"},"reference-count":224,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-024-02978-1","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:56Z","timestamp":1707508916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["New advances in medical management of dry eye: optimizing treatment strategies for enhanced relief"],"prefix":"10.1007","volume":"44","author":[{"given":"Toktam","family":"Shahraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Baradaran-Rafii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Ayyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jarstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Memar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"issue":"3","key":"2978_CR1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F et al (2017) TFOS DEWS II epidemiology report. Ocul Surf 15(3):334\u2013365","journal-title":"Ocul Surf"},{"key":"2978_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jtos.2021.10.007","volume":"23","author":"MK Morthen","year":"2022","unstructured":"Morthen MK, Magno MS, Utheim TP, Snieder H, Jansonius N, Hammond CJ et al (2022) The vision-related burden of dry eye. Ocul Surf 23:207\u2013215","journal-title":"Ocul Surf"},{"key":"2978_CR3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jtos.2021.05.006","volume":"21","author":"MK Morthen","year":"2021","unstructured":"Morthen MK, Magno MS, Utheim TP, Snieder H, Hammond CJ, Vehof J (2021) The physical and mental burden of dry eye disease: a large population-based study investigating the relationship with health-related quality of life and its determinants. Ocul Surf 21:107\u2013117","journal-title":"Ocul Surf"},{"issue":"3","key":"2978_CR4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039209","volume":"11","author":"P Hossain","year":"2021","unstructured":"Hossain P, Siffel C, Joseph C, Meunier J, Markowitz JT, Dana R (2021) Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey. BMJ Open 11(3):e039209","journal-title":"BMJ Open"},{"issue":"4","key":"2978_CR5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","volume":"30","author":"J Yu","year":"2011","unstructured":"Yu J, Asche CV, Fairchild CJ (2011) The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 30(4):379\u2013387","journal-title":"Cornea"},{"issue":"4","key":"2978_CR6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/09286580600801044","volume":"13","author":"JP Clegg","year":"2006","unstructured":"Clegg JP, Guest JF, Lehman A, Smith AF (2006) The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. Ophthalmic Epidemiol 13(4):263\u2013274","journal-title":"Ophthalmic Epidemiol"},{"key":"2978_CR7","volume":"8","author":"W Yang","year":"2021","unstructured":"Yang W, Luo Y, Wu S, Niu X, Yan Y, Qiao C et al (2021) Estimated annual economic burden of dry eye disease based on a multi-center analysis in china: a retrospective study. Front Med 8:771352","journal-title":"Front Med"},{"issue":"2","key":"2978_CR8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","volume":"14","author":"M McDonald","year":"2016","unstructured":"McDonald M, Patel DA, Keith MS, Snedecor SJ (2016) Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review. Ocul Surf 14(2):144\u2013167","journal-title":"Ocul Surf"},{"issue":"6","key":"2978_CR9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00003226-199811000-00002","volume":"17","author":"ME Stern","year":"1998","unstructured":"Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC (1998) The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 17(6):584\u2013589","journal-title":"Cornea"},{"issue":"4","key":"2978_CR10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK et al (2017) TFOS DEWS II report executive summary. Ocul Surf 15(4):802\u2013812","journal-title":"Ocul Surf"},{"issue":"1","key":"2978_CR11","doi-asserted-by":"crossref","first-page":"P286","DOI":"10.1016\/j.ophtha.2018.10.023","volume":"126","author":"EK Akpek","year":"2019","unstructured":"Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, Lin A, Rhee MK et al (2019) Dry eye syndrome preferred practice pattern\u00ae. Ophthalmology 126(1):P286-p334","journal-title":"Ophthalmology"},{"key":"2978_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106206","volume":"175","author":"HB Mohamed","year":"2022","unstructured":"Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA (2022) Current trends in pharmaceutical treatment of dry eye disease: a review. Eur J Pharm Sci 175:106206","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"2978_CR13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/bjophthalmol-2019-315747","volume":"105","author":"P Aragona","year":"2021","unstructured":"Aragona P, Giannaccare G, Mencucci R, Rubino P, Cantera E, Rolando M (2021) Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review. Br J Ophthalmol 105(4):446","journal-title":"Br J Ophthalmol"},{"issue":"2 Suppl","key":"2978_CR14","first-page":"S23","volume":"27","author":"JD Dunn","year":"2021","unstructured":"Dunn JD, Karpecki PM, Meske ME, Reissman D (2021) Evolving knowledge of the unmet needs in dry eye disease. Am J Manag Care 27(2 Suppl):S23-s32","journal-title":"Am J Manag Care"},{"issue":"2","key":"2978_CR15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/imm.13243","volume":"161","author":"M Guzm\u00e1n","year":"2020","unstructured":"Guzm\u00e1n M, Miglio M, Keitelman I, Shiromizu CM, Sabbione F, Fuentes F et al (2020) Transient tear hyperosmolarity disrupts the neuroimmune homeostasis of the ocular surface and facilitates dry eye onset. Immunology 161(2):148\u2013161","journal-title":"Immunology"},{"issue":"5","key":"2978_CR16","first-page":"71","volume":"112","author":"EM Messmer","year":"2015","unstructured":"Messmer EM (2015) The pathophysiology, diagnosis, and treatment of dry eye disease. Deutsch Arzteblatt Int 112(5):71\u201381; quiz 2","journal-title":"Deutsch Arzteblatt Int"},{"key":"2978_CR17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/ICO.0b013e318225415a","volume":"31","author":"M Lemp","year":"2012","unstructured":"Lemp M, Crews L, Bron A, Foulks G, Sullivan B (2012) Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea 31:472\u2013478","journal-title":"Cornea"},{"issue":"8","key":"2978_CR18","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1167\/iovs.14-14689","volume":"55","author":"PM Azcarate","year":"2014","unstructured":"Azcarate PM, Venincasa VD, Feuer W, Stanczyk F, Schally AV, Galor A (2014) Androgen deficiency and dry eye syndrome in the aging male. Invest Ophthalmol Vis Sci 55(8):5046\u20135053","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"2978_CR19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10792-017-0524-4","volume":"38","author":"M Rolando","year":"2018","unstructured":"Rolando M, Cantera E, Mencucci R, Rubino P, Aragona P (2018) The correct diagnosis and therapeutic management of tear dysfunction: recommendations of the P.I.C.A.S.S.O. board. Int Ophthalmol 38(2):875\u2013895","journal-title":"Int Ophthalmol"},{"issue":"2","key":"2978_CR20","first-page":"321","volume":"42","author":"S Bacman","year":"2001","unstructured":"Bacman S, Berra A, Sterin-Borda L, Borda E (2001) Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sj\u00f6gren syndrome. Invest Ophthalmol Vis Sci 42(2):321\u2013327","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"2978_CR21","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.4103\/ijo.IJO_604_20","volume":"68","author":"J Vazirani","year":"2020","unstructured":"Vazirani J, Donthineni PR, Goel S, Sane SS, Mahuvakar S, Narang P et al (2020) Chronic cicatrizing conjunctivitis: a review of the differential diagnosis and an algorithmic approach to management. Indian J Ophthalmol 68(11):2349\u20132355","journal-title":"Indian J Ophthalmol"},{"key":"2978_CR22","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109191","volume":"222","author":"A Vereertbrugghen","year":"2022","unstructured":"Vereertbrugghen A, Galletti JG (2022) Corneal nerves and their role in dry eye pathophysiology. Exp Eye Res 222:109191","journal-title":"Exp Eye Res"},{"issue":"4","key":"2978_CR23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1167\/iovs.10-6997b","volume":"52","author":"JD Nelson","year":"2011","unstructured":"Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S et al (2011) The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 52(4):1930\u20131937","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2978_CR24","doi-asserted-by":"crossref","first-page":"8267","DOI":"10.1038\/s41598-020-64999-x","volume":"10","author":"C Ranti","year":"2020","unstructured":"Ranti C, Jones W, Klin A, Shultz S (2020) Blink rate patterns provide a reliable measure of individual engagement with scene content. Sci Rep 10(1):8267","journal-title":"Sci Rep"},{"key":"2978_CR25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12886-016-0364-4","volume":"16","author":"J Moon","year":"2016","unstructured":"Moon J, Kim KW, Moon N (2016) Smartphone use is a risk factor for pediatric dry eye disease according to region and age: a case control study. BMC Ophthalmol 16:188","journal-title":"BMC Ophthalmol"},{"key":"2978_CR26","unstructured":"Dutta P (2022) Increased screen time and severity of asthenopic and ocular dryness symptoms during COVID-19 pandemic. Vis Dev Rehabil"},{"key":"2978_CR27","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1097\/ICL.0000000000000643","volume":"46","author":"K Tsubota","year":"2020","unstructured":"Tsubota K, Yokoi N, Watanabe H, Dogru M, Kojima T, Yamada M et al (2020) A new perspective on dry eye classification: proposal by the asia dry eye society. Eye Contact Lens 46:s2\u2013s13","journal-title":"Eye Contact Lens"},{"key":"2978_CR28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.preteyeres.2018.11.007","volume":"71","author":"C Baudouin","year":"2019","unstructured":"Baudouin C, Rolando M, Benitez Del Castillo JM, Messmer EM, Figueiredo FC, Irkec M et al (2019) Reconsidering the central role of mucins in dry eye and ocular surface diseases. Prog Retin Eye Res 71:68\u201387","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"2978_CR29","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1167\/iovs.16-19298","volume":"57","author":"LH Colorado","year":"2016","unstructured":"Colorado LH, Alzahrani Y, Pritchard N, Efron N (2016) Time course of changes in goblet cell density in symptomatic and asymptomatic contact lens wearers. Invest Ophthalmol Vis Sci 57(6):2888\u20132894","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"2978_CR30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/00003226-200111000-00009","volume":"20","author":"PJ Pisella","year":"2001","unstructured":"Pisella PJ, Malet F, Lejeune S, Brignole F, Debbasch C, Bara J et al (2001) Ocular surface changes induced by contact lens wear. Cornea 20(8):820\u2013825","journal-title":"Cornea"},{"issue":"4","key":"2978_CR31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F (2010) Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 29(4):312\u2013334","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"2978_CR32","first-page":"211","volume":"32","author":"S Dis","year":"2018","unstructured":"Dis S, Agnifili L, Cecannecchia S, A DIG, Ciancaglini M, (2018) In vivo analysis of prostaglandins-induced ocular surface and periocular adnexa modifications in patients with Glaucoma. In vivo (Athens, Greece). 32(2):211\u2013220","journal-title":"In vivo (Athens, Greece)."},{"issue":"12","key":"2978_CR33","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1167\/iovs.18-24690","volume":"59","author":"Y Su","year":"2018","unstructured":"Su Y, Liang Q, Su G, Wang N, Baudouin C, Labb\u00e9 A (2018) Spontaneous eye blink patterns in dry eye: clinical correlations. Invest Ophthalmol Vis Sci 59(12):5149\u20135156","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"2978_CR34","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1136\/bjophthalmol-2014-306453","volume":"99","author":"P Arriola-Villalobos","year":"2015","unstructured":"Arriola-Villalobos P, Fern\u00e1ndez-Vigo JI, D\u00edaz-Valle D, Peraza-Nieves JE, Fern\u00e1ndez-P\u00e9rez C, Ben\u00edtez-Del-Castillo JM (2015) Assessment of lower tear meniscus measurements obtained with Keratograph and agreement with Fourier-domain optical-coherence tomography. Br J Ophthalmol 99(8):1120\u20131125","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 1","key":"2978_CR35","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/ICL.0000000000000312","volume":"44","author":"M Shinzawa","year":"2018","unstructured":"Shinzawa M, Dogru M, Miyasaka K, Shimazaki J, Sekiryu T (2018) Application of CASIA SS-1000 optical coherence tomography tear meniscus imaging in testing the efficacy of new strip meniscometry in dry eye diagnosis. Eye Contact Lens 44(Suppl 1):S44\u2013S49","journal-title":"Eye Contact Lens"},{"issue":"6","key":"2978_CR36","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1167\/iovs.10-5505","volume":"52","author":"A Veres","year":"2011","unstructured":"Veres A, Tapaszt\u00f3 B, Kosina-Hagy\u00f3 K, Somfai GM, N\u00e9meth J (2011) Imaging lid-parallel conjunctival folds with OCT and comparing its grading with the slit lamp classification in dry eye patients and normal subjects. Invest Ophthalmol Vis Sci 52(6):2945\u20132951","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 2","key":"2978_CR37","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1097\/ICL.0000000000000435","volume":"44","author":"H Pult","year":"2018","unstructured":"Pult H, Bandlitz S (2018) Lid-Parallel Conjunctival Folds and Their Ability to Predict Dry Eye. Eye Contact Lens 44(Suppl 2):S113\u2013S119","journal-title":"Eye Contact Lens"},{"issue":"11","key":"2978_CR38","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjophthalmol-2012-301580","volume":"96","author":"J N\u00e9meth","year":"2012","unstructured":"N\u00e9meth J, Fodor E, Lang Z, Kosina-Hagy\u00f3 K, Berta A, Kom\u00e1r T et al (2012) Lid-parallel conjunctival folds (LIPCOF) and dry eye: a multicentre study. Br J Ophthalmol 96(11):1380\u20131385","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"2978_CR39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtos.2019.07.009","volume":"18","author":"J Woods","year":"2020","unstructured":"Woods J, Hutchings N, Srinivasan S, Jones L (2020) Geographic distribution of corneal staining in symptomatic dry eye. Ocul Surf 18(2):258\u2013266","journal-title":"Ocul Surf"},{"issue":"4","key":"2978_CR40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jcjo.2015.05.007","volume":"50","author":"Y Eom","year":"2015","unstructured":"Eom Y, Lee J-S, Keun Lee H, Myung Kim H, Suk SJ (2015) Comparison of conjunctival staining between lissamine green and yellow filtered fluorescein sodium. Can J Ophthalmol 50(4):273\u2013277","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"2978_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12177-008-9006-2","volume":"1","author":"M Senchyna","year":"2008","unstructured":"Senchyna M, Wax MB (2008) Quantitative assessment of tear production: a review of methods and utility in dry eye drug discovery. J Ocular Biol Dis Inform 1(1):1\u20136","journal-title":"J Ocular Biol Dis Inform"},{"issue":"1","key":"2978_CR42","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1038\/s41598-022-09791-9","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Fan X, Wu Y, Mou Y, Min J, Jin X (2022) Rear 4-min Schirmer test, a modified indicator of Schirmer test in diagnosing dry eye. Sci Rep 12(1):6272","journal-title":"Sci Rep"},{"issue":"4","key":"2978_CR43","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bjophthalmol-2014-305183","volume":"99","author":"TY Su","year":"2015","unstructured":"Su TY, Ho WT, Lu CY, Chang SW, Chiang HK (2015) Correlations among ocular surface temperature difference value, the tear meniscus height, Schirmer\u2019s test and fluorescein tear film break up time. Br J Ophthalmol 99(4):482\u2013487","journal-title":"Br J Ophthalmol"},{"key":"2978_CR44","first-page":"1","volume":"39","author":"J Paugh","year":"2019","unstructured":"Paugh J, Tse J, Nguyen T, Sasai A, Chen E, Jesus M et al (2019) Efficacy of the fluorescein tear breakup time test in dry eye. Cornea 39:1","journal-title":"Cornea"},{"issue":"5","key":"2978_CR45","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ajo.2010.10.032","volume":"151","author":"MA Lemp","year":"2011","unstructured":"Lemp MA, Bron AJ, Baudouin C, Ben\u00edtez Del Castillo JM, Geffen D, Tauber J et al (2011) Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 151(5):792\u20138.e1","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2978_CR46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/tvst.7.5.31","volume":"7","author":"JY Park","year":"2018","unstructured":"Park JY, Kim BG, Kim JS, Hwang JH (2018) Matrix metalloproteinase 9 point-of-care immunoassay result predicts response to topical cyclosporine treatment in dry eye disease. Transl Vis Sci Technol. 7(5):31","journal-title":"Transl Vis Sci Technol."},{"issue":"12","key":"2978_CR47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/iovs.61.12.9","volume":"61","author":"E Ponzini","year":"2020","unstructured":"Ponzini E, Scotti L, Grandori R, Tavazzi S, Zambon A (2020) Lactoferrin concentration in human tears and ocular diseases: a meta-analysis. Investig Ophthalmol Vis Sci 61(12):9","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"2978_CR48","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12886-020-01667-8","volume":"20","author":"J Li","year":"2020","unstructured":"Li J, Ma J, Hu M, Yu J, Zhao Y (2020) Assessment of tear film lipid layer thickness in patients with Meibomian gland dysfunction at different ages. BMC Ophthalmol 20(1):394","journal-title":"BMC Ophthalmol"},{"key":"2978_CR49","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/943786","volume":"2014","author":"M Kawashima","year":"2014","unstructured":"Kawashima M, Uchino M, Yokoi N, Uchino Y, Dogru M, Komuro A et al (2014) The association between dry eye disease and physical activity as well as sedentary behavior: results from the Osaka study. J Ophthalmol 2014:943786","journal-title":"J Ophthalmol"},{"issue":"5","key":"2978_CR50","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3390\/nu12051289","volume":"12","author":"I Molina-Leyva","year":"2020","unstructured":"Molina-Leyva I, Molina-Leyva A, Riquelme-Gallego B, Cano-Ib\u00e1\u00f1ez N, Garc\u00eda-Molina L, Bueno-Cavanillas A (2020) Effectiveness of mediterranean diet implementation in dry eye parameters: a study of PREDIMED-PLUS trial. Nutrients 12(5):1289","journal-title":"Nutrients"},{"key":"2978_CR51","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.974530","volume":"9","author":"T Inaba","year":"2022","unstructured":"Inaba T, Ohnishi-Kameyama M, Liu Y, Tanaka Y, Kobori M, Tamaki S et al (2022) Quercetin improves lacrimal gland function through its anti-oxidant actions: evidence from animal studies, and a pilot study in healthy human volunteers. Front Nutr 9:974530","journal-title":"Front Nutr"},{"issue":"4","key":"2978_CR52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/ICO.0b013e31826671ab","volume":"32","author":"AA Abusharha","year":"2013","unstructured":"Abusharha AA, Pearce EI (2013) The effect of low humidity on the human tear film. Cornea 32(4):429\u2013434","journal-title":"Cornea"},{"issue":"2","key":"2978_CR53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/OPX.0000000000000778","volume":"93","author":"G Shen","year":"2016","unstructured":"Shen G, Qi Q, Ma X (2016) Effect of moisture chamber spectacles on tear functions in dry eye disease. Optom Vis Sci Off Publ Am Acad Optom 93(2):158\u2013164","journal-title":"Optom Vis Sci Off Publ Am Acad Optom"},{"issue":"1","key":"2978_CR54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12886-018-0700-y","volume":"18","author":"Y Ren","year":"2018","unstructured":"Ren Y, Chen J, Zheng Q, Chen W (2018) Short-term effect of a developed warming moist chamber goggle for video display terminal-associated dry eye. BMC Ophthalmol 18(1):33","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"2978_CR55","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1755-3768.2012.02485.x","volume":"91","author":"M Hirayama","year":"2013","unstructured":"Hirayama M, Murat D, Liu Y, Kojima T, Kawakita T, Tsubota K (2013) Efficacy of a novel moist cool air device in office workers with dry eye disease. Acta Ophthalmol 91(8):756\u2013762","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"2978_CR56","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/aos.15105","volume":"100","author":"B Kam\u00f8y","year":"2022","unstructured":"Kam\u00f8y B, Magno M, N\u00f8land ST, Moe MC, Petrovski G, Vehof J et al (2022) Video display terminal use and dry eye: preventive measures and future perspectives. Acta Ophthalmol 100(7):723\u2013739","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"2978_CR57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.exer.2003.09.020","volume":"78","author":"N Yokoi","year":"2004","unstructured":"Yokoi N, Komuro A (2004) Non-invasive methods of assessing the tear film. Exp Eye Res 78(3):399\u2013407","journal-title":"Exp Eye Res"},{"issue":"5","key":"2978_CR58","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ophtha.2014.12.018","volume":"122","author":"R Arita","year":"2015","unstructured":"Arita R, Morishige N, Koh S, Shirakawa R, Kawashima M, Sakimoto T et al (2015) Increased tear fluid production as a compensatory response to meibomian gland loss: a multicenter cross-sectional study. Ophthalmology 122(5):925\u2013933","journal-title":"Ophthalmology"},{"key":"2978_CR59","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2017.05.022","volume":"180","author":"N Yokoi","year":"2017","unstructured":"Yokoi N, Georgiev GA, Kato H, Komuro A, Sonomura Y, Sotozono C et al (2017) Classification of fluorescein breakup patterns: a novel method of differential diagnosis for dry eye. Am J Ophthalmol 180:72\u201385","journal-title":"Am J Ophthalmol"},{"key":"2978_CR60","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/jop.2017.0052","volume":"33","author":"J-S Garrigue","year":"2017","unstructured":"Garrigue J-S, Amrane M, Faure M-O, Holopainen J, Tong L (2017) Relevance of lipid-based products in the management of dry eye disease. J Ocular Pharmacol Ther. 33:647","journal-title":"J Ocular Pharmacol Ther."},{"issue":"1","key":"2978_CR61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jtos.2016.08.004","volume":"15","author":"A Lambiase","year":"2017","unstructured":"Lambiase A, Sullivan BD, Schmidt TA, Sullivan DA, Jay GD, Truitt ER 3rd et al (2017) A two-week, randomized, double-masked study to evaluate safety and efficacy of lubricin (150 \u03bcg\/mL) eye drops versus sodium hyaluronate (HA) 0.18% eye drops (Vismed\u00ae) in patients with moderate dry eye disease. Ocul Surf 15(1):77\u201387","journal-title":"Ocul Surf"},{"issue":"3","key":"2978_CR62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ejca.2008.09.032","volume":"45","author":"A Bottomley","year":"2009","unstructured":"Bottomley A, Jones D, Claassens L (2009) Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur J Cancer 45(3):347\u2013353","journal-title":"Eur J Cancer"},{"issue":"8","key":"2978_CR63","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/diagnostics10080559","volume":"10","author":"Y Okumura","year":"2020","unstructured":"Okumura Y, Inomata T, Iwata N, Sung J, Fujimoto K, Fujio K et al (2020) A Review of dry eye questionnaires: measuring patient-reported outcomes and health-related quality of life. Diagnostics 10(8):559","journal-title":"Diagnostics"},{"key":"2978_CR64","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/112067210501500602","volume":"15","author":"J Spain","year":"2005","unstructured":"Spain J, Nemeth J, Germany H, Kaynak P, Horwarth-Winthers J, India A et al (2005) The triple classification of dry eye for practical clinical use. Eur J Ophthalmol 15:660\u2013667","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"2978_CR65","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/01.ico.0000214802.40313.fa","volume":"25","author":"A Behrens","year":"2006","unstructured":"Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT et al (2006) Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 25(8):900\u2013907","journal-title":"Cornea"},{"key":"2978_CR66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","volume":"5","author":"M Lemp","year":"2007","unstructured":"Lemp M (2007) The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workShop (2007). Ocul Surf 5:75\u201392","journal-title":"Ocul Surf"},{"issue":"9","key":"2978_CR67","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/bjophthalmol-2013-304619","volume":"98","author":"C Baudouin","year":"2014","unstructured":"Baudouin C, Aragona P, Van Setten G, Rolando M, Irke\u00e7 M, Ben\u00edtezdelCastillo J et al (2014) Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol 98(9):1168\u20131176","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"2978_CR68","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1120672120960586","volume":"31","author":"S Barabino","year":"2021","unstructured":"Barabino S, Aragona P, di Zazzo A, Rolando M (2021) Updated definition and classification of dry eye disease: renewed proposals using the nominal group and Delphi techniques. Eur J Ophthalmol 31(1):42\u201348","journal-title":"Eur J Ophthalmol"},{"key":"2978_CR69","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2147\/OPTH.S351898","volume":"16","author":"A Rodriguez-Garcia","year":"2022","unstructured":"Rodriguez-Garcia A, Babayan-Sosa A, Ramirez-Miranda A, Cruz-Valdes C, Hernandez-Quintela E, Hernandez-Camarena J et al (2022) A practical approach to severity classification and treatment of dry eye disease: a proposal from the Mexican dry eye disease expert panel. Clin Ophthalmol (Auckland, NZ) 16:1331\u20131355","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"6","key":"2978_CR70","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/112067210501500602","volume":"15","author":"J Murube","year":"2005","unstructured":"Murube J, N\u00e9meth J, H\u00f6h H, Kaynak-Hekimhan P, Horwath-Winter J, Agarwal A et al (2005) The triple classification of dry eye for practical clinical use. Eur J Ophthalmol 15(6):660\u2013667","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"2978_CR71","doi-asserted-by":"crossref","first-page":"27699","DOI":"10.1038\/srep27699","volume":"6","author":"Y Uchino","year":"2016","unstructured":"Uchino Y, Uchino M, Yokoi N, Dogru M, Kawashima M, Komuro A et al (2016) Impact of cigarette smoking on tear function and correlation between conjunctival goblet cells and tear MUC5AC concentration in office workers. Sci Rep 6(1):27699","journal-title":"Sci Rep"},{"issue":"2","key":"2978_CR72","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archopht.1995.01100020037025","volume":"113","author":"K Tsubota","year":"1995","unstructured":"Tsubota K, Nakamori K (1995) Effects of ocular surface area and blink rate on tear dynamics (Chicago, Ill\u202f: 1960). Archiv Ophthalmol 113(2):155\u2013158","journal-title":"Archiv Ophthalmol"},{"issue":"10","key":"2978_CR73","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/ICO.0b013e318206caee","volume":"30","author":"MY Su","year":"2011","unstructured":"Su MY, Perry HD, Barsam A, Perry AR, Donnenfeld ED, Wittpenn JR et al (2011) The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy. Cornea 30(10):1098\u20131104","journal-title":"Cornea"},{"key":"2978_CR74","first-page":"251584141987036","volume":"11","author":"SL Haber","year":"2019","unstructured":"Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B (2019) Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol 11:2515841419870366","journal-title":"Ther Adv Ophthalmol"},{"issue":"5","key":"2978_CR75","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/ICO.0000000000001884","volume":"38","author":"G Giannaccare","year":"2019","unstructured":"Giannaccare G, Pellegrini M, Sebastiani S, Bernabei F, Roda M, Taroni L et al (2019) Efficacy of omega-3 fatty acid supplementation for treatment of dry eye disease: a meta-analysis of randomized clinical trials. Cornea 38(5):565\u2013573","journal-title":"Cornea"},{"key":"2978_CR76","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100842","volume":"78","author":"T Kojima","year":"2020","unstructured":"Kojima T, Dogru M, Kawashima M, Nakamura S, Tsubota K (2020) Advances in the diagnosis and treatment of dry eye. Prog Retin Eye Res 78:100842","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"2978_CR77","first-page":"327","volume":"2","author":"Q Pan","year":"2017","unstructured":"Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK (2017) Autologous serum eye drops for dry eye. Cochrane Database Syst Rev 2(2):327","journal-title":"Cochrane Database Syst Rev"},{"key":"2978_CR78","first-page":"1913","volume":"16","author":"H He","year":"2010","unstructured":"He H, Ding H, Liao A, Liu Q, Yang J, Zhong X (2010) Effects of mycophenolate mofetil on proliferation and mucin-5AC expression in human conjunctival goblet cells in vitro. Mol Vis 16:1913\u20131919","journal-title":"Mol Vis"},{"issue":"3","key":"2978_CR79","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/14656566.2010.518612","volume":"12","author":"M Dogru","year":"2011","unstructured":"Dogru M, Tsubota K (2011) Pharmacotherapy of dry eye. Expert Opin Pharmacother 12(3):325\u2013334","journal-title":"Expert Opin Pharmacother"},{"key":"2978_CR80","doi-asserted-by":"crossref","first-page":"436","DOI":"10.5935\/0004-2749.20190097","volume":"82","author":"M Ribeiro","year":"2019","unstructured":"Ribeiro M, Barbosa F, Ribeiro L, Sousa-Rodrigues C, Ribeiro E (2019) Effectiveness of using preservative-free artificial tears versus preserved lubricants for the treatment of dry eyes: a systematic review. Arq Bras Oftalmol 82:436\u2013445","journal-title":"Arq Bras Oftalmol"},{"key":"2978_CR81","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.clae.2018.12.003","volume":"42","author":"C Lievens","year":"2018","unstructured":"Lievens C, Berdy G, Douglass D, Montaquila S, Lin H, Simmons P et al (2018) Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study. Contact Lens Anterior Eye. 42:443","journal-title":"Contact Lens Anterior Eye."},{"issue":"4","key":"2978_CR82","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.clae.2018.12.003","volume":"42","author":"C Lievens","year":"2019","unstructured":"Lievens C, Berdy G, Douglass D, Montaquila S, Lin H, Simmons P et al (2019) Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: a multicenter, double-masked, randomized 30-day study. Contact Lens Anterior Eye J Br Contact Lens Assoc 42(4):443\u2013449","journal-title":"Contact Lens Anterior Eye J Br Contact Lens Assoc"},{"issue":"13","key":"2978_CR83","first-page":"3152","volume":"43","author":"WC Prather","year":"2002","unstructured":"Prather WC, Stoecker JF, Vehige JG, Simmons PA (2002) Clinical performance of a new mid-viscosity artificial tear for dry eye treatment. Invest Ophthalmol V Sci 43(13):3152","journal-title":"Invest Ophthalmol V Sci"},{"key":"2978_CR84","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/aos.15159","volume":"100","author":"L Hynnekleiv","year":"2022","unstructured":"Hynnekleiv L, Magno M, Vernhardsdottir R, Moschowits E, T\u00f8nseth K, Dartt D et al (2022) Hyaluronic acid in the treatment of dry eye disease. Acta Ophthalmol 100:844","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"2978_CR85","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3390\/ijerph18052383","volume":"18","author":"YJ Yang","year":"2021","unstructured":"Yang YJ, Lee WY, Kim YJ, Hong YP (2021) A meta-analysis of the efficacy of hyaluronic acid eye drops for the treatment of dry eye syndrome. Int J Environ Res Public Health 18(5):2383","journal-title":"Int J Environ Res Public Health"},{"key":"2978_CR86","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.3390\/ijms21103516","volume":"21","author":"T Kojima","year":"2020","unstructured":"Kojima T, Nagata T, Kudo H, Mueller-Lierheim W, van Setten G, Dogru M et al (2020) The effects of high molecular weight hyaluronic acid eye drop application in environmental dry eye stress model mice. Int J Mol Sci 21:3516","journal-title":"Int J Mol Sci"},{"key":"2978_CR87","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/jop.2020.0011","volume":"36","author":"P Daull","year":"2020","unstructured":"Daull P, Amrane M, Ismail D, Cwiklik L, Baudouin C, Leonardi A et al (2020) Cationic emulsion-based artificial tears as a mimic of functional healthy tear film for restoration of ocular surface homeostasis in dry eye disease. J Ocular Pharmacol Ther 36:355","journal-title":"J Ocular Pharmacol Ther"},{"key":"2978_CR88","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.3390\/ijms22052747","volume":"22","author":"P Eftimov","year":"2021","unstructured":"Eftimov P, Yokoi N, Melo A, Daull P (2021) Interactions of meibum and tears with mucomimetic polymers: a hint towards the interplay between the layers of the tear film. Int J Mol Sci 22:2747","journal-title":"Int J Mol Sci"},{"key":"2978_CR89","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/jop.2020.0119","volume":"37","author":"E Hernandez","year":"2021","unstructured":"Hernandez E, Taisne C, Lussignol M, Esclatine A, Labetoulle M (2021) Commercially available eye drops containing trehalose protect against dry conditions via autophagy induction. J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther 37:386","journal-title":"J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"issue":"5","key":"2978_CR90","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.3390\/ijms23052434","volume":"23","author":"M Labetoulle","year":"2022","unstructured":"Labetoulle M, Benitez-del-Castillo JM, Barabino S, Herrero Vanrell R, Daull P, Garrigue J-S et al (2022) Artificial tears: biological role of their ingredients in the management of dry eye disease. Int J Mol Sci [Internet]. 23(5):2434","journal-title":"Int J Mol Sci [Internet]."},{"key":"2978_CR91","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1089\/jop.2017.0008","volume":"34","author":"C Bucolo","year":"2017","unstructured":"Bucolo C, Fidilio A, Platania C, Geraci F, Lazzara F, Drago F (2017) Antioxidant and Osmoprotecting activity of Taurine in dry eye models. J Ocular Pharmacol Ther 34:188","journal-title":"J Ocular Pharmacol Ther"},{"issue":"2","key":"2978_CR92","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clae.2009.12.007","volume":"33","author":"JP Craig","year":"2010","unstructured":"Craig JP, Purslow C, Murphy PJ, Wolffsohn JSW (2010) Effect of a liposomal spray on the pre-ocular tear film. Cont Lens Anterior Eye 33(2):83\u201387","journal-title":"Cont Lens Anterior Eye"},{"key":"2978_CR93","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clae.2009.12.007","volume":"33","author":"J Craig","year":"2010","unstructured":"Craig J, Purslow C, Murphy P, Wolffsohn J (2010) Effect of a liposomal spray on the pre-ocular tear film. Contact Lens Anterior Eye J Br Contact Lens Assoc 33:83\u201387","journal-title":"Contact Lens Anterior Eye J Br Contact Lens Assoc"},{"key":"2978_CR94","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clae.2012.05.003","volume":"35","author":"H Pult","year":"2012","unstructured":"Pult H, Gill F, Riede-Pult B (2012) Effect of three different liposomal eye sprays on ocular comfort and tear film. Contact Lens Anterior Eye J Br Contact Lens Assoc 35:203\u2013207","journal-title":"Contact Lens Anterior Eye J Br Contact Lens Assoc"},{"key":"2978_CR95","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4236\/ojoph.2017.72015","volume":"7","author":"A Hueck","year":"2017","unstructured":"Hueck A, Wehrmann R (2017) Comparison of the clinical efficacy of four different liposomal sprays for the treatment of dry eye. Open J Ophthalmol 7:103\u2013116","journal-title":"Open J Ophthalmol"},{"key":"2978_CR96","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/ICL.0000000000000788","volume":"47","author":"H Pult","year":"2021","unstructured":"Pult H, Khatum F, Trav\u00e9 Huarte S, Wolffsohn J (2021) Effect of eye spray phospholipid concentration on the tear film and ocular comfort. Eye Contact Lens Sci Clin Pract 47:445\u2013448","journal-title":"Eye Contact Lens Sci Clin Pract"},{"key":"2978_CR97","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clae.2017.11.004","volume":"41","author":"D Acar","year":"2017","unstructured":"Acar D, Molina-Mart\u00ednez I, G\u00f3mez-Ballesteros M, Guzm\u00e1n-Navarro M, Ben\u00edtez-del-Castillo J, Herrero-Vanrell R (2017) Novel liposome-based and in situ gelling artificial tear formulation for dry eye disease treatment. Contact Lens Anterior Eye. 41:93\u201398","journal-title":"Contact Lens Anterior Eye."},{"issue":"14","key":"2978_CR98","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-022-01782-4","volume":"82","author":"JE Frampton","year":"2022","unstructured":"Frampton JE (2022) Varenicline solution nasal spray: a review in dry eye disease. Drugs 82(14):1481\u20131488","journal-title":"Drugs"},{"issue":"4","key":"2978_CR99","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","volume":"129","author":"D Wirta","year":"2022","unstructured":"Wirta D, Vollmer P, Paauw J, Chiu KH, Henry E, Striffler K et al (2022) Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial. Ophthalmology 129(4):379\u2013387","journal-title":"Ophthalmology"},{"key":"2978_CR100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtos.2021.12.007","volume":"24","author":"H Quiroz-Mercado","year":"2022","unstructured":"Quiroz-Mercado H, Hernandez-Quintela E, Chiu KH, Henry E, Nau JA (2022) A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study. Ocul Surf 24:15\u201321","journal-title":"Ocul Surf"},{"issue":"9","key":"2978_CR101","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.clinthera.2022.07.006","volume":"44","author":"GL Torkildsen","year":"2022","unstructured":"Torkildsen GL, Pattar GR, Jerkins G, Striffler K, Nau J (2022) Efficacy and safety of single-dose OC-02 (Simpinicline Solution) nasal spray on signs and symptoms of dry eye disease: the PEARL Phase II randomized trial. Clin Ther 44(9):1178\u20131186","journal-title":"Clin Ther"},{"issue":"3","key":"2978_CR102","first-page":"292","volume":"41","author":"JS L\u00f3pez-Garc\u00eda","year":"2016","unstructured":"L\u00f3pez-Garc\u00eda JS, Garc\u00eda-Lozano I, Rivas L, Ram\u00edrez N, M\u00e9ndez MT, Raposo R (2016) Stability of growth factors in autologous serum eyedrops after long-term storage. Curr Eye Res 41(3):292\u2013298","journal-title":"Curr Eye Res"},{"key":"2978_CR103","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/bjo.2003.026211","volume":"88","author":"BA Noble","year":"2004","unstructured":"Noble BA, Loh R, Maclennan S, Pesudovs K, Reynolds A, Bridges LR et al (2004) Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 88:647\u2013652","journal-title":"Br J Ophthalmol"},{"key":"2978_CR104","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/aos.14788","volume":"99","author":"P Van der Meer","year":"2021","unstructured":"Van der Meer P, Verbakel S, Honohan \u00c1, Lorinser J, Thurlings R, Jacobs J et al (2021) Allogeneic and autologous serum eye drops: a pilot double-blind randomized crossover trial. Acta Ophthalmol 99:837\u2013842","journal-title":"Acta Ophthalmol"},{"key":"2978_CR105","doi-asserted-by":"crossref","unstructured":"Higuchi A (2018) Autologous serum and serum components. Investigative Ophthalmol V Sci ;59(14):DES121-DES9.","DOI":"10.1167\/iovs.17-23760"},{"key":"2978_CR106","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/bjo.2003.025528","volume":"88","author":"R Lagnado","year":"2004","unstructured":"Lagnado R, King A, Donald F, Dua H (2004) A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. Br J Ophthalmol 88:464\u2013465","journal-title":"Br J Ophthalmol"},{"key":"2978_CR107","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1159\/000505630","volume":"63","author":"L Wang","year":"2019","unstructured":"Wang L, Cao K, Wei Z, Baudouin C, Labb\u00e9 A, Liang Q (2019) Autologous serum eye drops versus artificial tear drops for dry eye disease: a systematic review and meta-analysis of randomized controlled trials. Ophthalmic Res 63:443\u2013451","journal-title":"Ophthalmic Res"},{"key":"2978_CR108","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.exer.2015.02.016","volume":"135","author":"E Anitua","year":"2015","unstructured":"Anitua E, Fuente M, Muruzabal F, Riestra A, Merayo-Lloves J, Orive G (2015) Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Exp Eye Res 135:118\u2013126","journal-title":"Exp Eye Res"},{"issue":"1","key":"2978_CR109","doi-asserted-by":"crossref","first-page":"8906","DOI":"10.1038\/s41598-022-12879-x","volume":"12","author":"C Metheetrairut","year":"2022","unstructured":"Metheetrairut C, Ngowyutagon P, Tunganuntarat A, Khowawisetsut L, Kittisares K, Prabhasawat P (2022) Comparison of epitheliotrophic factors in platelet-rich plasma versus autologous serum and their treatment efficacy in dry eye disease. Sci Rep 12(1):8906","journal-title":"Sci Rep"},{"key":"2978_CR110","doi-asserted-by":"crossref","unstructured":"Ribeiro M, Melo V, Barbosa M, Tozzi M, Ramos M, Gaia N, et al (2017) The use of platelet rich-plasma in Ophthalmology: a literature review. Revista Brasileira de Oftalmologia;76","DOI":"10.5935\/0034-7280.20170067"},{"key":"2978_CR111","first-page":"e170","volume":"97","author":"V Garc\u00eda-Conca","year":"2018","unstructured":"Garc\u00eda-Conca V, Abad-Collado M, Hueso-Abancens J, Mengual-Verd\u00fa E, Pinero D, Aguirre-Balsalobre F et al (2018) Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma. Acta Ophthalmol 97:e170\u2013e178","journal-title":"Acta Ophthalmol"},{"key":"2978_CR112","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jop.2016.0166","volume":"33","author":"R Sanchez-Avila","year":"2017","unstructured":"Sanchez-Avila R, Merayo-Lloves J, Riestra A, Anitua E, Muruzabal F, Orive G et al (2017) The effect of immunologically safe plasma rich in growth factor eye drops in patients with Sj\u00f6gren syndrome. J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther 33:391\u2013399","journal-title":"J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"key":"2978_CR113","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/tvst.9.6.22","volume":"9","author":"A Rodriguez","year":"2020","unstructured":"Rodriguez A, Gisbert S, Palaz\u00f3n A, Ali\u00f3 J (2020) Quantification of growth factors and Fibronectin in diverse preparations of platelet-rich plasma for the treatment of ocular surface disorders (E-PRP). Transl Vis Sci Technol 9:22","journal-title":"Transl Vis Sci Technol"},{"key":"2978_CR114","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jcms.2018.10.017","volume":"47","author":"D Steller","year":"2018","unstructured":"Steller D, Herbst N, Pries R, Juhl D, Hakim S (2018) Impact of incubation method on the release of growth factors in Non-Ca2+-activated PRP, Ca2+-activated PRP, PRF and A-PRF. J Cranio-Maxillofac Surg 47:365\u2013372","journal-title":"J Cranio-Maxillofac Surg"},{"issue":"1","key":"2978_CR115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12886-022-02554-0","volume":"22","author":"MA Mohammed","year":"2022","unstructured":"Mohammed MA, Allam IY, Shaheen MS, Lazreg S, Doheim MF (2022) Lacrimal gland injection of platelet rich plasma for treatment of severe dry eye: a comparative clinical study. BMC Ophthalmol 22(1):343","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"2978_CR116","first-page":"529","volume":"14","author":"E Anitua","year":"1999","unstructured":"Anitua E (1999) Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 14(4):529\u2013535","journal-title":"Int J Oral Maxillofac Implants"},{"issue":"12","key":"2978_CR117","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1097\/ICO.0b013e31820d86d6","volume":"30","author":"S L\u00f3pez-Plandolit","year":"2011","unstructured":"L\u00f3pez-Plandolit S, Morales MC, Freire V, Grau AE, Dur\u00e1n JA (2011) Efficacy of plasma rich in growth factors for the treatment of dry eye. Cornea 30(12):1312\u20131317","journal-title":"Cornea"},{"key":"2978_CR118","first-page":"357","volume":"31","author":"S Gea-Navarrete","year":"2021","unstructured":"Gea-Navarrete S, Montero-Hern\u00e1ndez M, Gallego-Lago I, Santiuste-Rom\u00e1n A, Montesinos-Ort\u00ed S, Soler-Company E (2021) Resultados en salud y aspectos farmaco-econ\u00f3micos del tratamiendo con PRGF-Endoret en ojo seco. Revista de la OFIL 31:357\u2013360","journal-title":"Revista de la OFIL"},{"issue":"2","key":"2978_CR119","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000487951","volume":"60","author":"RM Sanchez-Avila","year":"2018","unstructured":"Sanchez-Avila RM, Merayo-Lloves J, Fernandez ML, Rodriguez-Gutierrez LA, Jurado N, Muruzabal F et al (2018) Plasma rich in growth factors for the treatment of dry eye after LASIK surgery. Ophthalmic Res 60(2):80\u201386","journal-title":"Ophthalmic Res"},{"key":"2978_CR120","first-page":"8406832","volume":"2016","author":"AM Fea","year":"2016","unstructured":"Fea AM, Aragno V, Testa V, Machetta F, Parisi S, D\u2019Antico S et al (2016) The effect of autologous platelet lysate eye drops: an in vivo confocal microscopy study. Biomed Res Int 2016:8406832","journal-title":"Biomed Res Int"},{"issue":"8","key":"2978_CR121","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1111\/aos.12710","volume":"93","author":"E Anitua","year":"2015","unstructured":"Anitua E, Muruzabal F, Tayebba A, Riestra A, Perez VL, Merayo-Lloves J et al (2015) Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol 93(8):e605\u2013e614","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"2978_CR122","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bmt.2016.221","volume":"52","author":"S Pezzotta","year":"2017","unstructured":"Pezzotta S, Del Fante C, Scudeller L, Rossi GC, Perotti C, Bianchi PE et al (2017) Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD. Bone Marrow Transpl 52(1):101\u2013106","journal-title":"Bone Marrow Transpl"},{"key":"2978_CR123","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40123-020-00239-9","volume":"9","author":"G Giannaccare","year":"2020","unstructured":"Giannaccare G, Carnevali A, Senni C, Logozzo L, Scorcia V (2020) Umbilical cord blood and serum for the treatment of ocular diseases: a comprehensive review. Ophthalmol Therapy 9:235\u2013248","journal-title":"Ophthalmol Therapy"},{"key":"2978_CR124","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/ICO.0b013e3182580762","volume":"32","author":"P Versura","year":"2012","unstructured":"Versura P, Profazio V, Buzzi M, Stancari A, Arpinati M, Malavolta N, Campos EC (2012) Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye. Cornea 32:412\u2013418","journal-title":"Cornea"},{"key":"2978_CR125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bmt.1705566","volume":"39","author":"KC Yoon","year":"2007","unstructured":"Yoon KC, Jeong IY, Im S-S, Park YG, Kim HJ, Choi J (2007) Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease. Bone Marrow Transpl 39:231\u2013235","journal-title":"Bone Marrow Transpl"},{"key":"2978_CR126","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ajo.2007.03.016","volume":"144","author":"KC Yoon","year":"2007","unstructured":"Yoon KC, Heo H, Im S-K, You I-C, Kim Y-H, Park Y-G (2007) Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol 144:86\u201392","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2978_CR127","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4068\/cmj.2014.50.3.82","volume":"50","author":"KC Yoon","year":"2014","unstructured":"Yoon KC (2014) Use of umbilical cord serum in ophthalmology. Chonnam Med J 50(3):82\u201385","journal-title":"Chonnam Med J"},{"key":"2978_CR128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/02713680601147690","volume":"32","author":"A Higuchi","year":"2007","unstructured":"Higuchi A, Ueno R, Shimmura S, Suematsu M, Dogru M, Tsubota K (2007) Albumin rescues ocular epithelial cells from cell death in dry eye. Curr Eye Res 32:83\u201388","journal-title":"Curr Eye Res"},{"key":"2978_CR129","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/bjo.87.10.1279","volume":"87","author":"S Shimmura","year":"2003","unstructured":"Shimmura S, Ueno R, Matsumoto Y, Goto E, Higuchi A, Shimazaki J et al (2003) Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol 87:1279\u20131283","journal-title":"Br J Ophthalmol"},{"key":"2978_CR130","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/jop.2014.0161","volume":"31","author":"M Schargus","year":"2015","unstructured":"Schargus M, Kohlhaas M, Unterlauft J (2015) Treatment of severe ocular surface disorders with albumin eye drops. J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther 31:291\u2013295","journal-title":"J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"issue":"4","key":"2978_CR131","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/ICU.0b013e3283543b61","volume":"23","author":"A Lambiase","year":"2012","unstructured":"Lambiase A, Sacchetti M, Bonini S (2012) Nerve growth factor therapy for corneal disease. Curr Opin Ophthalmol 23(4):296\u2013302","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"2978_CR132","first-page":"275","volume":"28","author":"MP Ferrari","year":"2014","unstructured":"Ferrari MP, Mantelli F, Sacchetti M, Antonangeli MI, Cattani F, D\u2019Anniballe G et al (2014) Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. BioDrugs Clin Immunother Biopharm Gene Therapy 28(3):275\u2013283","journal-title":"BioDrugs Clin Immunother Biopharm Gene Therapy"},{"issue":"1","key":"2978_CR133","first-page":"127","volume":"104","author":"M Sacchetti","year":"2020","unstructured":"Sacchetti M, Lambiase A, Schmidl D, Schmetterer L, Ferrari M, Mantelli F et al (2020) Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. Br J Ophthalmol 104(1):127\u2013135","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"2978_CR134","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.ophtha.2018.03.004","volume":"125","author":"S Bonini","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P, Filatori I, Allegretti M, Chao W et al (2018) Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 125(9):1468\u20131471","journal-title":"Ophthalmology"},{"issue":"9","key":"2978_CR135","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","volume":"125","author":"S Bonini","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W et al (2018) Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 125(9):1332\u20131343","journal-title":"Ophthalmology"},{"issue":"2","key":"2978_CR136","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10561-017-9618-5","volume":"18","author":"K Jirsova","year":"2017","unstructured":"Jirsova K, Jones GLA (2017) Amniotic membrane in ophthalmology: properties, preparation, storage and indications for grafting-a review. Cell Tissue Banking 18(2):193\u2013204","journal-title":"Cell Tissue Banking"},{"key":"2978_CR137","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/OPTH.S203510","volume":"13","author":"E Yeu","year":"2019","unstructured":"Yeu E, Goldberg DF, Mah FS, Beckman KA, Luchs JI, Solomon JD et al (2019) Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease. Clin Ophthalmol (Auckland, NZ) 13:887\u2013894","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"9","key":"2978_CR138","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1442-9071.2009.02159.x","volume":"37","author":"L Liang","year":"2009","unstructured":"Liang L, Li W, Ling S, Sheha H, Qiu W, Li C et al (2009) Amniotic membrane extraction solution for ocular chemical burns. Clin Exp Ophthalmol 37(9):855\u2013863","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"2978_CR139","first-page":"459","volume":"20","author":"N Shayan Asl","year":"2019","unstructured":"Shayan Asl N, Nejat F, Mohammadi P, Nekoukar A, Hesam S, Ebrahimi M et al (2019) Amniotic membrane extract eye drop promotes limbal stem cell proliferation and corneal epithelium healing. Cell J 20(4):459\u2013468","journal-title":"Cell J"},{"key":"2978_CR140","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/OPTH.S165553","volume":"12","author":"MS Murri","year":"2018","unstructured":"Murri MS, Moshirfar M, Birdsong OC, Ronquillo YC, Ding Y, Hoopes PC (2018) Amniotic membrane extract and eye drops: a review of literature and clinical application. Clin Ophthalmol (Auckland, NZ) 12:1105\u20131112","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"3","key":"2978_CR141","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10561-021-09962-4","volume":"23","author":"ML P\u00e9rez","year":"2022","unstructured":"P\u00e9rez ML, Barreales S, Sabater-Cruz N, Martinez-Conesa EM, Vilarrodona A, Casaroli-Marano RP (2022) Amniotic membrane extract eye drops: a new approach to severe ocular surface pathologies. Cell Tissue Banking 23(3):473\u2013481","journal-title":"Cell Tissue Banking"},{"key":"2978_CR142","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2147\/OPTH.S300047","volume":"15","author":"K Ryu","year":"2021","unstructured":"Ryu K, Kim S, Kim MK, Paik H, Kim DH (2021) Short-term therapeutic effects of topical corticosteroids on refractory dry eye disease: clinical usefulness of matrix metalloproteinase 9 testing as a response prediction marker. Clin Ophthalmol 15:759\u2013767","journal-title":"Clin Ophthalmol"},{"key":"2978_CR143","first-page":"1","volume":"37","author":"M Kallab","year":"2019","unstructured":"Kallab M, Szegedi S, Hommer N, Stegmann H, Kaya S, Werkmeister R et al (2019) Topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial. Adv Ther 37:1\u201313","journal-title":"Adv Ther"},{"key":"2978_CR144","first-page":"757","volume":"13","author":"H Leibowitz","year":"1974","unstructured":"Leibowitz H, Kupferman A (1974) Anti-inflammatory effectiveness in the cornea of topically administered prednisolone. Invest Ophthalmol 13:757\u2013763","journal-title":"Invest Ophthalmol"},{"key":"2978_CR145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ophtha.2005.09.033","volume":"113","author":"H Lee","year":"2006","unstructured":"Lee H, Ryu I, Seo KY, Hong S, Kim H, Kim E (2006) Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology 113:198\u2013205","journal-title":"Ophthalmology"},{"key":"2978_CR146","first-page":"1","volume":"27","author":"CA Cutolo","year":"2017","unstructured":"Cutolo CA, Barabino S, Bonzano C, Traverso C (2017) The use of topical corticosteroids for treatment of dry eye syndrome. Ocul Immunol Inflamm 27:1\u201310","journal-title":"Ocul Immunol Inflamm"},{"key":"2978_CR147","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/ICO.0b013e3181b765a6","volume":"29","author":"J Jonisch","year":"2010","unstructured":"Jonisch J, Steiner A, Udell I (2010) Preservative-free low-dose dexamethasone for the treatment of chronic ocular surface disease refractory to standard therapy. Cornea 29:723\u2013726","journal-title":"Cornea"},{"key":"2978_CR148","first-page":"633","volume":"5","author":"M Patane","year":"2011","unstructured":"Patane M, Cohen A, From S, Torkildsen G, Welch D, Ousler G (2011) Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol (Auckland, NZ) 5:633\u2013643","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"2978_CR149","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/bjo.39.2.90","volume":"39","author":"S Eadie","year":"1955","unstructured":"Eadie S, Thompson M (1955) Kerato-conjunctivitis sicca treated with Cortisone and ACTH. Br J Ophthalmol 39:90\u201397","journal-title":"Br J Ophthalmol"},{"key":"2978_CR150","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/jop.2020.0014","volume":"36","author":"K Beckman","year":"2020","unstructured":"Beckman K, Katz J, Majmudar P, Rostov A (2020) Loteprednol etabonate for the treatment of dry eye disease: a literature review. J Ocular Pharmacol Ther 36:497\u2013511","journal-title":"J Ocular Pharmacol Ther"},{"key":"2978_CR151","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4068\/cmj.2015.51.1.26","volume":"51","author":"H Jung","year":"2015","unstructured":"Jung H, Ji Y, Sung M, Kim K, Yoon KC (2015) Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with sj\u00f6gren\u2019s syndrome. Chonnam Med J 51:26\u201332","journal-title":"Chonnam Med J"},{"key":"2978_CR152","doi-asserted-by":"crossref","unstructured":"Aragona P, Spinella R, Rania L, Postorino E, Sommario M, Roszkowska A, et al. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjogren syndrome. European journal of ophthalmology. 2012;23:0.","DOI":"10.5301\/ejo.5000229"},{"issue":"2","key":"2978_CR153","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5114\/ceji.2016.60995","volume":"41","author":"AM Ambroziak","year":"2016","unstructured":"Ambroziak AM, Szaflik J, Szaflik JP, Ambroziak M, Witkiewicz J, Skopi\u0144ski P (2016) Immunomodulation on the ocular surface: a review. Central-Eur J Immunol 41(2):195\u2013208","journal-title":"Central-Eur J Immunol"},{"issue":"3","key":"2978_CR154","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX et al (2017) TFOS DEWS II management and therapy report. Ocul Surf 15(3):575\u2013628","journal-title":"Ocul Surf"},{"key":"2978_CR155","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2147\/OPTH.S184412","volume":"13","author":"RC de Oliveira","year":"2019","unstructured":"de Oliveira RC, Wilson SE (2019) Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol (Auckland, NZ) 13:1115\u20131122","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"Pt 1","key":"2978_CR156","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1042\/BJ20040669","volume":"383","author":"Y Li","year":"2004","unstructured":"Li Y, Johnson N, Capano M, Edwards M, Crompton M (2004) Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. Biochem J 383(Pt 1):101\u2013109","journal-title":"Biochem J"},{"key":"2978_CR157","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/OPTH.S188521","volume":"13","author":"AJ Kanellopoulos","year":"2019","unstructured":"Kanellopoulos AJ (2019) Incidence and management of symptomatic dry eye related to LASIK for myopia, with topical cyclosporine A. Clin Ophthalmol (Auckland, NZ) 13:545\u2013552","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"2978_CR158","doi-asserted-by":"crossref","unstructured":"Lee JH, Song IS, Kim KL, Yoon SY (2016) Effectiveness and optical quality of topical 3.0% diquafosol versus 0.05% cyclosporine a in dry eye patients following cataract surgery. J oPhthalmol:8150757","DOI":"10.1155\/2016\/8150757"},{"issue":"5","key":"2978_CR159","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/eye.2017.3","volume":"31","author":"B Iaccheri","year":"2017","unstructured":"Iaccheri B, Torroni G, Cagini C, Fiore T, Cerquaglia A, Lupidi M et al (2017) Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine. Eye (Lond) 31(5):788\u2013794","journal-title":"Eye (Lond)"},{"issue":"4","key":"2978_CR160","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","volume":"107","author":"K Sall","year":"2000","unstructured":"Sall K, Stevenson OD, Mundorf TK, Reis BL (2000) Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology 107(4):631\u2013639","journal-title":"Ophthalmology"},{"key":"2978_CR161","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/OPTH.S101627","volume":"10","author":"KG Stonecipher","year":"2016","unstructured":"Stonecipher KG, Torkildsen GL, OuslerMorris GWS, Villanueva L, Hollander DA (2016) The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. Clin Ophthalmol (Auckland, NZ). 10:887\u2013895","journal-title":"Clin Ophthalmol (Auckland, NZ)."},{"issue":"9","key":"2978_CR162","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","volume":"126","author":"DF Goldberg","year":"2019","unstructured":"Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD (2019) A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology 126(9):1230\u20131237","journal-title":"Ophthalmology"},{"issue":"10","key":"2978_CR163","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/ICO.0000000000001989","volume":"38","author":"R Malhotra","year":"2019","unstructured":"Malhotra R, Devries DK, Luchs J, Kabat A, Schechter BA, Shen Lee B et al (2019) Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b\/3 and phase 3 studies. Cornea 38(10):1259\u20131265","journal-title":"Cornea"},{"issue":"7","key":"2978_CR164","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2018.0106","volume":"35","author":"SL Weiss","year":"2019","unstructured":"Weiss SL, Kramer WG (2019) Ocular distribution of cyclosporine following topical administration of OTX-101 in New Zealand white rabbits. J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther 35(7):395\u2013402","journal-title":"J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"issue":"2","key":"2978_CR165","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11095-018-2556-5","volume":"36","author":"A Mandal","year":"2019","unstructured":"Mandal A, Gote V, Pal D, Ogundele A, Mitra AK (2019) Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa\u00ae) for dry eye disease. Pharm Res 36(2):36","journal-title":"Pharm Res"},{"issue":"17","key":"2978_CR166","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s40265-017-0834-x","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Ciclosporin ophthalmic emulsion 0.1%: a review in severe dry eye disease. Drugs 77(17):1909\u20131916","journal-title":"Drugs"},{"issue":"4","key":"2978_CR167","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue JS, Figueiredo FC et al (2016) Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 26(4):287\u2013296","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"2978_CR168","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/jop.2015.0078","volume":"32","author":"AI Gire","year":"2016","unstructured":"Gire AI, Karakus S, Ingrodi SM, Akpek EK (2016) Frequent dosing of topical cyclosporine a for severe ocular surface disease. J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther 32(3):150\u2013154","journal-title":"J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"issue":"5","key":"2978_CR169","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","volume":"107","author":"D Stevenson","year":"2000","unstructured":"Stevenson D, Tauber J, Reis BL (2000) Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group. Ophthalmology 107(5):967\u2013974","journal-title":"Ophthalmology"},{"issue":"7","key":"2978_CR170","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1185\/030079905X50615","volume":"21","author":"K Stonecipher","year":"2005","unstructured":"Stonecipher K, Perry HD, Gross RH, Kerney DL (2005) The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin 21(7):1057\u20131063","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"2978_CR171","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/ICL.0000000000000049","volume":"40","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Donnenfeld ED, Holland EJ, Slonim CB, Solomon R, Solomon KD et al (2014) Effect of loteprednol etabonate 05% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens 40(5):289\u2013296","journal-title":"Eye Contact Lens"},{"issue":"3","key":"2978_CR172","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/tjo.tjo_15_18","volume":"9","author":"S Singla","year":"2019","unstructured":"Singla S, Sarkar L, Joshi M (2019) Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: a prospective study. Taiwan J Ophthalmol 9(3):173\u2013178","journal-title":"Taiwan J Ophthalmol"},{"issue":"6","key":"2978_CR173","first-page":"603","volume":"27","author":"SN Rao","year":"2011","unstructured":"Rao SN (2011) Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal. J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther 27(6):603\u2013609","journal-title":"J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"key":"2978_CR174","first-page":"A762","volume":"28","author":"I Rey","year":"2021","unstructured":"Rey I, Barcia M, Garc\u00eda Quintanilla L, Castro-Balado A, Busto-Iglesias M, Zarra-Ferro I et al (2021) 4CPS-323 Evaluation of the use, adherence and tolerance of 0.03% tacrolimus eye drops. Eur J Hosp Pharm 28:A762","journal-title":"Eur J Hosp Pharm"},{"issue":"10","key":"2978_CR175","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","volume":"23","author":"JM Barbarino","year":"2013","unstructured":"Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB (2013) PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genom 23(10):563\u2013585","journal-title":"Pharmacogenet Genom"},{"issue":"4","key":"2978_CR176","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.anai.2019.01.004","volume":"122","author":"H Yazu","year":"2019","unstructured":"Yazu H, Shimizu E, Aketa N, Dogru M, Okada N, Fukagawa K et al (2019) The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol 122(4):387\u201392.e1","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol"},{"issue":"1","key":"2978_CR177","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1120672121992680","volume":"32","author":"P Moawad","year":"2022","unstructured":"Moawad P, Shamma R, Hassanein D, Ragab G, El Zawahry O (2022) Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome. Eur J Ophthalmol 32(1):673\u2013679","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"2978_CR178","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/ICO.0b013e31823f8c9b","volume":"31","author":"BK Moscovici","year":"2012","unstructured":"Moscovici BK, Holzchuh R, Chiacchio BB, Santo RM, Shimazaki J, Hida RY (2012) Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea 31(8):945\u2013949","journal-title":"Cornea"},{"issue":"5","key":"2978_CR179","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clae.2015.04.004","volume":"38","author":"BK Moscovici","year":"2015","unstructured":"Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, Hoshino-Ruiz DR, Albers MB, Santo RM et al (2015) Treatment of Sj\u00f6gren\u2019s syndrome dry eye using 0.03% tacrolimus eye drop: prospective double-blind randomized study. Contact Lens Anterior Eye J Br Contact Lens Assoc 38(5):373\u2013378","journal-title":"Contact Lens Anterior Eye J Br Contact Lens Assoc"},{"issue":"1","key":"2978_CR180","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","volume":"124","author":"EJ Holland","year":"2017","unstructured":"Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K et al (2017) Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology 124(1):53\u201360","journal-title":"Ophthalmology"},{"issue":"2","key":"2978_CR181","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jtos.2016.01.001","volume":"14","author":"VL Perez","year":"2016","unstructured":"Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R (2016) Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf 14(2):207\u2013215","journal-title":"Ocul Surf"},{"issue":"1","key":"2978_CR182","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molimm.2012.11.006","volume":"55","author":"S Schmidt","year":"2013","unstructured":"Schmidt S, Moser M, Sperandio M (2013) The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol 55(1):49\u201358","journal-title":"Mol Immunol"},{"issue":"17","key":"2978_CR183","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3390\/jcm11175014","volume":"11","author":"JX Li","year":"2022","unstructured":"Li JX, Tsai YY, Lai CT, Li YL, Wu YH, Chiang CC (2022) Lifitegrast ophthalmic solution 5% is a safe and efficient eyedrop for dry eye disease: a systematic review and meta-analysis. J Clin Med 11(17):5014","journal-title":"J Clin Med"},{"issue":"6","key":"2978_CR184","first-page":"741","volume":"35","author":"ED Donnenfeld","year":"2016","unstructured":"Donnenfeld ED, Karpecki PM, Majmudar PA, Nichols KK, Raychaudhuri A, Roy M et al (2016) Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized. Placebo-Controlled Study. Cornea. 35(6):741\u2013748","journal-title":"Placebo-Controlled Study. Cornea."},{"issue":"6","key":"2978_CR185","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1060028015574593","volume":"49","author":"DJ Wilson","year":"2015","unstructured":"Wilson DJ, Schutte SM, Abel SR (2015) Comparing the efficacy of ophthalmic NSAIDs in common indications: a literature review to support cost-effective prescribing. Ann Pharmacother 49(6):727\u2013734","journal-title":"Ann Pharmacother"},{"issue":"11","key":"2978_CR186","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/ICO.0b013e31824988e5","volume":"31","author":"X Liu","year":"2012","unstructured":"Liu X, Wang S, Kao AA, Long Q (2012) The effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes. Cornea 31(11):1235\u20131239","journal-title":"Cornea"},{"key":"2978_CR187","doi-asserted-by":"crossref","unstructured":"Bai R, Liu L-p, Chen Z, Ma Q (2022) Cyclosporine (0.05%) combined with Diclofenac sodium eye drops for the treatment of dry eye disease. J Ophthalmol :2334077","DOI":"10.1155\/2022\/2334077"},{"key":"2978_CR188","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/OPTH.S101836","volume":"10","author":"A Kawahara","year":"2016","unstructured":"Kawahara A, Utsunomiya T, Kato Y, Takayanagi Y (2016) Comparison of effect of nepafenac and diclofenac ophthalmic solutions on cornea, tear film, and ocular surface after cataract surgery: the results of a randomized trial. Clin Ophthalmol (Auckland, NZ) 10:385\u2013391","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"2978_CR189","first-page":"741","volume":"7","author":"K Yanai","year":"2013","unstructured":"Yanai K, Huang J, Kadonosono K, Uchio E (2013) Corneal sensitivity after topical bromfenac sodium eye-drop instillation. Clin Ophthalmol (Auckland, NZ) 7:741\u2013744","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"6","key":"2978_CR190","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000074074","volume":"35","author":"Y Hayasaka","year":"2003","unstructured":"Hayasaka Y, Hayasaka S, Zhang XY, Nagaki Y (2003) Effects of topical corticosteroids and nonsteroidal anti-inflammatory drugs on prostaglandin e2-induced aqueous flare elevation in pigmented rabbits. Ophthalmic Res 35(6):341\u2013344","journal-title":"Ophthalmic Res"},{"key":"2978_CR191","doi-asserted-by":"crossref","unstructured":"Bai R, Liu LP, Chen Z, Ma Q (2022) Cyclosporine (0.05%) Combined with Diclofenac sodium eye drops for the treatment of dry eye disease. J Ophthalmol: 2334077.","DOI":"10.1155\/2022\/2334077"},{"key":"2978_CR192","first-page":"1447","volume":"8","author":"TG Coursey","year":"2014","unstructured":"Coursey TG, de Paiva CS (2014) Managing Sj\u00f6gren\u2019s Syndrome and non-Sj\u00f6gren syndrome dry eye with anti-inflammatory therapy. Clin Ophthalmol (Auckland, NZ) 8:1447\u20131458","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"5","key":"2978_CR193","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/ICO.0000000000000309","volume":"34","author":"DD Singer","year":"2015","unstructured":"Singer DD, Kennedy J, Wittpenn JR (2015) Topical NSAIDs effect on corneal sensitivity. Cornea 34(5):541\u2013543","journal-title":"Cornea"},{"issue":"5","key":"2978_CR194","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.eye.6701537","volume":"19","author":"P Aragona","year":"2005","unstructured":"Aragona P, Stilo A, Ferreri F, Mobrici M (2005) Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sj\u00f6gren\u2019s syndrome patients. Eye (Lond) 19(5):535\u2013539","journal-title":"Eye (Lond)"},{"issue":"11","key":"2978_CR195","volume":"379","author":"C Maayan","year":"2018","unstructured":"Maayan C, Heyman SN (2018) Dry eye. N Engl J Med 379(11):e19","journal-title":"N Engl J Med"},{"issue":"9","key":"2978_CR196","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/jop.2017.0052","volume":"33","author":"JS Garrigue","year":"2017","unstructured":"Garrigue JS, Amrane M, Faure MO, Holopainen JM, Tong L (2017) Relevance of lipid-based products in the management of dry eye disease. J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther 33(9):647\u2013661","journal-title":"J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"key":"2978_CR197","first-page":"1583","volume":"20","author":"A Liu","year":"2014","unstructured":"Liu A, Ji J (2014) Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies. Med Sci Monit Int Med J Exp Clin Res 20:1583\u20131589","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"2978_CR198","doi-asserted-by":"crossref","unstructured":"Downie LE, Ng SM, Lindsley KB, Akpek EK. (2019) Omega\u20103 and omega\u20106 polyunsaturated fatty acids for dry eye disease. Cochrane Database Syst Rev. (12):","DOI":"10.1002\/14651858.CD011016.pub2"},{"issue":"11","key":"2978_CR199","first-page":"826","volume":"64","author":"J Ton","year":"2018","unstructured":"Ton J, Korownyk C (2018) Omega-3 supplements for dry eye. Can Fam Phys Medecin de famille canadien 64(11):826","journal-title":"Can Fam Phys Medecin de famille canadien"},{"issue":"5","key":"2978_CR200","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1089\/jop.2021.0102","volume":"38","author":"C Jacobi","year":"2022","unstructured":"Jacobi C, Angstmann-Mehr S, Lange A, Kaercher T (2022) A water-free omega-3 fatty acid eye drop formulation for the treatment of evaporative dry eye disease: a prospective, multicenter noninterventional study. J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther 38(5):348\u2013353","journal-title":"J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"issue":"8","key":"2978_CR201","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40265-015-0409-7","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM (2015) Diquafosol ophthalmic solution 3 %: a review of its use in dry eye. Drugs 75(8):911\u2013922","journal-title":"Drugs"},{"issue":"10","key":"2978_CR202","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3109\/02713683.2015.1122813","volume":"41","author":"J Baek","year":"2016","unstructured":"Baek J, Doh SH, Chung SK (2016) The effect of topical diquafosol tetrasodium 3% on dry eye after cataract surgery. Curr Eye Res 41(10):1281\u20131285","journal-title":"Curr Eye Res"},{"issue":"7","key":"2978_CR203","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/jop.2015.0081","volume":"32","author":"HS Jeon","year":"2016","unstructured":"Jeon HS, Hyon JY (2016) The efficacy of diquafosol ophthalmic solution in Non-Sj\u00f6gren and Sj\u00f6gren syndrome dry eye patients unresponsive to artificial tear. J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther 32(7):463\u2013468","journal-title":"J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"issue":"10","key":"2978_CR204","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","volume":"119","author":"Y Matsumoto","year":"2012","unstructured":"Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K (2012) Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology 119(10):1954\u20131960","journal-title":"Ophthalmology"},{"issue":"10","key":"2978_CR205","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","volume":"96","author":"E Takamura","year":"2012","unstructured":"Takamura E, Tsubota K, Watanabe H, Ohashi Y (2012) A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol 96(10):1310\u20131315","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"2978_CR206","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1007\/s12325-021-01910-8","volume":"38","author":"T Ogami","year":"2021","unstructured":"Ogami T, Asano H, Hiraoka T, Yamada Y, Oshika T (2021) The effect of diquafosol ophthalmic solution on clinical parameters and visual function in soft contact lens-related dry eye. Adv Ther 38(11):5534\u20135547","journal-title":"Adv Ther"},{"key":"2978_CR207","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/OPTH.S122542","volume":"11","author":"Y Inoue","year":"2017","unstructured":"Inoue Y, Ochi S (2017) Effects of 3% diquafosol sodium ophthalmic solution on higher-order aberrations in patients diagnosed with dry eye after cataract surgery. Clin Ophthalmol (Auckland, NZ) 11:87\u201393","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"1","key":"2978_CR208","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12886-018-0910-3","volume":"18","author":"Y Mun","year":"2018","unstructured":"Mun Y, Kwon J-W, Oh JY (2018) Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease. BMC Ophthalmol 18(1):237","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"2978_CR209","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/jcm11020367","volume":"11","author":"M Uchino","year":"2022","unstructured":"Uchino M, Yokoi N, Shimazaki J, Hori Y, Tsubota K, Eye OBOTJD, S, (2022) Adherence to eye drops usage in dry eye patients and reasons for non-compliance: a web-based survey. J Clin Med 11(2):367","journal-title":"J Clin Med"},{"issue":"8","key":"2978_CR210","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1007\/s12325-022-02194-2","volume":"39","author":"Y Hori","year":"2022","unstructured":"Hori Y, Oka K, Inai M (2022) Efficacy and safety of the long-acting diquafosol ophthalmic solution DE-089C in patients with dry eye: a randomized, double-masked, placebo-controlled phase 3 study. Adv Ther 39(8):3654\u20133667","journal-title":"Adv Ther"},{"key":"2978_CR211","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2147\/OPTH.S40798","volume":"8","author":"T Kashima","year":"2014","unstructured":"Kashima T, Itakura H, Akiyama H, Kishi S (2014) Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal. Clin Ophthalmol (Auckland, NZ) 8:1003\u20131010","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"6","key":"2978_CR212","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.ico.0000126436.25751.fb","volume":"23","author":"H Urashima","year":"2004","unstructured":"Urashima H, Okamoto T, Takeji Y, Shinohara H, Fujisawa S (2004) Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea 23(6):613\u2013619","journal-title":"Cornea"},{"issue":"7","key":"2978_CR213","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1089\/jop.2012.0054","volume":"29","author":"M Ueta","year":"2013","unstructured":"Ueta M, Sotozono C, Yokoi N, Kinoshita S (2013) Rebamipide suppresses PolyI:C-stimulated cytokine production in human conjunctival epithelial cells. J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther 29(7):688\u2013693","journal-title":"J Ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"issue":"3","key":"2978_CR214","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/ojo.OJO_29_2017","volume":"11","author":"S Shrivastava","year":"2018","unstructured":"Shrivastava S, Patkar P, Ramakrishnan R, Kanhere M, Riaz Z (2018) Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes. Oman J Ophthalmol 11(3):207\u2013212","journal-title":"Oman J Ophthalmol"},{"issue":"1","key":"2978_CR215","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12886-015-0040-0","volume":"15","author":"K Ueda","year":"2015","unstructured":"Ueda K, Matsumiya W, Otsuka K, Maeda Y, Nagai T, Nakamura M (2015) Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol 15(1):58","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"2978_CR216","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","volume":"119","author":"S Kinoshita","year":"2012","unstructured":"Kinoshita S, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N (2012) Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology 119(12):2471\u20132478","journal-title":"Ophthalmology"},{"issue":"6","key":"2978_CR217","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","volume":"120","author":"S Kinoshita","year":"2013","unstructured":"Kinoshita S, Oshiden K, Awamura S, Suzuki H, Nakamichi N, Yokoi N (2013) A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology 120(6):1158\u20131165","journal-title":"Ophthalmology"},{"issue":"2","key":"2978_CR218","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","volume":"147","author":"EC Kim","year":"2009","unstructured":"Kim EC, Choi JS, Joo CK (2009) A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol 147(2):206\u201313.e3","journal-title":"Am J Ophthalmol"},{"key":"2978_CR219","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2147\/DDDT.S137825","volume":"11","author":"H Toshida","year":"2017","unstructured":"Toshida H, Funaki T, Ono K, Tabuchi N, Watanabe S, Seki T et al (2017) Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial. Drug Des Dev Ther 11:1871\u20131879","journal-title":"Drug Des Dev Ther"},{"issue":"6","key":"2978_CR220","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.3390\/nu13061998","volume":"13","author":"P Fogagnolo","year":"2021","unstructured":"Fogagnolo P, DeCilla\u2019 S, Alkabes M, Sabella P, Rossetti L (2021) A review of topical and systemic vitamin supplementation in ocular surface diseases. Nutrients [Internet]. 13(6):1998","journal-title":"Nutrients [Internet]."},{"issue":"2","key":"2978_CR221","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/112067210001000205","volume":"10","author":"H Selek","year":"2000","unstructured":"Selek H, Unl\u00fc N, Orhan M, Irke\u00e7 M (2000) Evaluation of retinoic acid ophthalmic emulsion in dry eye. Eur J Ophthalmol 10(2):121\u2013127","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"2978_CR222","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/IJG.0000000000000316","volume":"25","author":"X Cui","year":"2016","unstructured":"Cui X, Xiang J, Zhu W, Wei A, Le Q, Xu J et al (2016) Vitamin A palmitate and carbomer gel protects the conjunctiva of patients with long-term prostaglandin analogs application. J Glaucoma 25(6):487\u2013492","journal-title":"J Glaucoma"},{"issue":"10","key":"2978_CR223","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/S0161-6420(88)33009-5","volume":"95","author":"HK Soong","year":"1988","unstructured":"Soong HK, Martin NF, Wagoner MD, Alfonso E, Mandelbaum SH, Laibson PR et al (1988) Topical retinoid therapy for squamous metaplasia of various ocular surface disorders. A multicenter, placebo-controlled double-masked study. Ophthalmology 95(10):1442\u20131446","journal-title":"Ophthalmology"},{"issue":"6","key":"2978_CR224","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/jamaophthalmol.2013.2385","volume":"131","author":"TA Schmidt","year":"2013","unstructured":"Schmidt TA, Sullivan DA, Knop E, Richards SM, Knop N, Liu S et al (2013) Transcription, translation, and function of lubricin, a boundary lubricant, at the ocular surface. JAMA Ophthalmol 131(6):766\u2013776","journal-title":"JAMA Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-02978-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-02978-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-02978-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:45:25Z","timestamp":1741880725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-02978-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":224,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2978"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-02978-1","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"13 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"49"}}